Literature DB >> 31706040

Nanoparticles for multimodal antivascular therapeutics: Dual drug release, photothermal and photodynamic therapy.

Juan L Paris1, Gonzalo Villaverde2, Sergio Gómez-Graña2, María Vallet-Regí3.   

Abstract

The poor delivery of nanoparticles to target cancer cells hinders their success in the clinical setting. In this work, an alternative target readily available for circulating nanoparticles has been selected to eliminate the need for nanoparticle penetration in the tissue: the tumor blood vessels. A tumor endothelium-targeted nanoparticle (employing an RGD-containing peptide) capable of co-delivering two anti-vascular drugs (one anti-angiogenic drug and one vascular disruption agent) is here presented. Furthermore, the nanodevice presents two additional anti-vascular capabilities upon activation by Near-Infrared light: provoking local hyperthermia (by gold nanorods in the system) and generating toxic reactive oxygen species (by the presence of a photosensitizer). RGD-targeting is shown to increase uptake by HUVEC cells, and while the nanoparticles are shown not to be toxic for these cells, upon Near-Infrared irradiation their almost complete killing is achieved. The combination of all four therapeutic modalities is then evaluated in an ex ovo fibrosarcoma xenograft model, which shows a significant reduction in the number of blood vessels irrigating the xenografts when the nanoparticles are present, as well as the destruction of the existing blood vessels upon irradiation. These results suggest that the combination of different anti-vascular therapeutic strategies in a single nanocarrier appears promising and should be further explored in the future. STATEMENT OF SIGNIFICANCE MVR2019: The combination of antivascular drugs with different mechanisms of action (such as antiangiogenic drugs and vascular disruption agents) has been recently proposed as a promising approach to maximize the therapeutic potential of anti-vascular therapeutics. Given the capacity of nanoparticles to co-deliver different drugs in optimizable ratios, nanomedicine appears to have a huge potential for the development of this kind of multimodal antivascular. To showcase this, an multimodal anti-vascular nanodevice for cancer therapy is here presented. This tumor endothelium-targeted nanosystem is capable of co-delivering two anti-vascular drugs (anti-angiogenic and vascular disruption agent) while also providing two additional therapeutic modalities that can be activated by Near-Infrared light: provoking local hyperthermia (photothermal therapy) and generating toxic reactive oxygen species (photodynamic therapy).
Copyright © 2019. Published by Elsevier Ltd.

Entities:  

Keywords:  Anti-vascular; Mesoporous silica nanoparticles; Nanomedicine; Photodynamic therapy; Photothermal therapy

Mesh:

Substances:

Year:  2019        PMID: 31706040     DOI: 10.1016/j.actbio.2019.11.004

Source DB:  PubMed          Journal:  Acta Biomater        ISSN: 1742-7061            Impact factor:   8.947


  14 in total

1.  The Use of Alternative Strategies for Enhanced Nanoparticle Delivery to Solid Tumors.

Authors:  Mukaddes Izci; Christy Maksoudian; Bella B Manshian; Stefaan J Soenen
Journal:  Chem Rev       Date:  2021-01-14       Impact factor: 60.622

Review 2.  Nanotechnology for angiogenesis: opportunities and challenges.

Authors:  Saeid Kargozar; Francesco Baino; Sepideh Hamzehlou; Michael R Hamblin; Masoud Mozafari
Journal:  Chem Soc Rev       Date:  2020-06-15       Impact factor: 54.564

Review 3.  Non-Invasive Evaluation of Acute Effects of Tubulin Binding Agents: A Review of Imaging Vascular Disruption in Tumors.

Authors:  Li Liu; Devin O'Kelly; Regan Schuetze; Graham Carlson; Heling Zhou; Mary Lynn Trawick; Kevin G Pinney; Ralph P Mason
Journal:  Molecules       Date:  2021-04-27       Impact factor: 4.411

4.  Endostatin Genetically Engineered Placental Mesenchymal Stromal Cells Carrying Doxorubicin-Loaded Mesoporous Silica Nanoparticles for Combined Chemo- and Antiangiogenic Therapy.

Authors:  Paz de la Torre; Juan L Paris; Miguel Fernández-de la Torre; María Vallet-Regí; Ana I Flores
Journal:  Pharmaceutics       Date:  2021-02-10       Impact factor: 6.321

Review 5.  The Chorioallantoic Membrane Assay in Nanotoxicological Research-An Alternative for In Vivo Experimentation.

Authors:  Christoph R Buhr; Nadine Wiesmann; Rachel C Tanner; Jürgen Brieger; Jonas Eckrich
Journal:  Nanomaterials (Basel)       Date:  2020-11-24       Impact factor: 5.076

Review 6.  Influence of the Surface Functionalization on the Fate and Performance of Mesoporous Silica Nanoparticles.

Authors:  Miguel Gisbert-Garzarán; María Vallet-Regí
Journal:  Nanomaterials (Basel)       Date:  2020-05-09       Impact factor: 5.076

Review 7.  Mesoporous Silica Nanoparticles for the Treatment of Complex Bone Diseases: Bone Cancer, Bone Infection and Osteoporosis.

Authors:  Miguel Gisbert-Garzarán; Miguel Manzano; María Vallet-Regí
Journal:  Pharmaceutics       Date:  2020-01-20       Impact factor: 6.321

Review 8.  Ligand-Targeted Delivery of Photosensitizers for Cancer Treatment.

Authors:  Piotr Gierlich; Ana I Mata; Claire Donohoe; Rui M M Brito; Mathias O Senge; Lígia C Gomes-da-Silva
Journal:  Molecules       Date:  2020-11-14       Impact factor: 4.411

Review 9.  Gold nanoparticle‑mediated delivery of paclitaxel and nucleic acids for cancer therapy (Review).

Authors:  Zhiguang Wang; Jianyu Dong; Qiaojiajie Zhao; Ying Ying; Lijie Zhang; Junrong Zou; Shuqi Zhao; Jiuju Wang; Yuan Zhao; Shanshan Jiang
Journal:  Mol Med Rep       Date:  2020-10-11       Impact factor: 2.952

10.  Osteoporosis Remission and New Bone Formation with Mesoporous Silica Nanoparticles.

Authors:  Patricia Mora-Raimundo; Daniel Lozano; Manuel Benito; Francisca Mulero; Miguel Manzano; María Vallet-Regí
Journal:  Adv Sci (Weinh)       Date:  2021-06-06       Impact factor: 16.806

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.